Exhibit 10.11

Confidential treatment has been requested for portions of this exhibit. The copy
filed herewith omits the information subject to the confidentiality request.
Omissions are designated as [*]. A complete version of this exhibit has been
filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the
Securities Exchange Act of 1934, as amended.

Execution Copy

ROYALTY AGREEMENT

ROYALTY AGREEMENT, effective as of October 1, 2005, by and between AtriCure,
Inc. (“AtriCure”) with offices at 6033 Schumacher Park Drive, West Chester, OH
45069, and Randall K. Wolf, M.D. (“Wolf”) with offices at Department of Surgery,
University of Cincinnati College of Medicine, ML 0558, Cincinnati, OH
45267-0558.

WITNESSETH

WHEREAS, AtriCure is engaged in the business of, among other things, developing
technologies that provide doctors alternative, more expedient methods to ablate
tissue during surgical procedures and treat the left atrial appendage in order
to reduce the incidences of stroke;

WHEREAS, Wolf is the co-inventor of the Wolf Dissector (as defined below);

WHEREAS, through his working relationship with AtriCure, Wolf has provided
AtriCure with access to the Wolf Dissector to be used in AtriCure’s business;

WHEREAS, the parties desire to enter into this Agreement to set forth the terms
and conditions under which AtriCure will make royalty payments to Wolf with
respect to such use of the Wolf Dissector.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, and in consideration of the mutual promises
contained herein, AtriCure and Wolf hereby agree as follows:

1. Royalties. AtriCure shall pay to Wolf royalties for AtriCure’s use of the
Wolf Dissector, as well as for those inventions, improvements or ideas
contemplated in Section 2 below, at the royalty rates set forth in Schedule A
hereto or at such other percentage rates as may be agreed to between AtriCure
and Wolf (the “Royalties”). In no event shall the Royalties be less than $50,000
per quarter during the term of this Agreement; however, in no event shall the
Royalties in the aggregate exceed $2,000,000. The minimum fourth quarter 2005
Royalty of $50,000 shall be paid to Wolf in the fourth quarter of 2005. Any
further Royalty due Wolf for the fourth quarter of 2005 shall be paid no later
than January 15, 2006. Thereafter, Royalties shall be paid quarterly within
fifteen (15) days following the end of each quarter during the term of this
Agreement.

As used herein, the term “Wolf Dissector” shall mean the articulating,
illuminating disposable handpiece designed to perform a dissection or any
evolution of such device, including, but not limited to, the integration of such
device into the AtriCure bi-polar ablation system.

--------------------------------------------------------------------------------

2. Inventions. Wolf agrees to provide AtriCure with any inventions, improvements
or ideas made or conceived by Wolf within the field of atrial fibrillation
treatment, excluding (a) pharmacologic treatments for atrial fibrillation,
(b) pharmacology for stroke prevention, (c) devices designed specifically for
stroke prevention and (d) fat pad isolation techniques developed for [*], during
the term of this Agreement and for ninety (90) days after its termination. Wolf
agrees that any such inventions or ideas shall be the sole property of AtriCure
and Wolf shall execute, acknowledge and deliver to AtriCure all such further
documents and papers, including assignments, applications for patents and any
and all other documents and papers as maybe reasonably requested by AtriCure to
effectuate the provisions of this Section 2 and to permit AtriCure to publish or
protect said inventions, improvements and ideas by patent or otherwise in any
and all countries and to vest title to said patents, inventions, improvements
and ideas in AtriCure or its nominees, their successors or assigns. Wolf shall
render all such assistance as AtriCure may require in any patent office
proceeding or litigation involving said inventions, improvements or ideas.

3. Confidential Information. Any “Confidential Information” acquired by Wolf
from AtriCure or developed in the course of the relationship established
hereunder shall not be disclosed by Wolf to others or used Wolf for Wolf’s own
benefit or the benefit of any third party without the prior written consent of
AtriCure. “Confidential Information” includes: any and all proprietary or
confidential data, methods, techniques, processes, formulas, designs, drawings,
models, trade secrets, inventions, ideas, know-how, technical information,
business records, technical data, test results, financial data or information,
marketing data or plans, customer information, pricing information, product
specifications, and any and all information of any nature whatsoever embodied or
included in any of the foregoing, in whatever medium recorded or contained; but
shall not include: (a) information which is or becomes, through no fault of
Wolf, generally known to the public; or (b) information received by Wolf on a
non-confidential basis from a source other than AtriCure, provided that Wolf has
no reason to believe that such source is or was under a duty of confidentiality
to AtriCure. Upon termination of this Agreement, Wolf will return to AtriCure
all records, data, notes, reports and other documents or property containing
Confidential Information furnished by AtriCure or developed pursuant to the
relationship established hereunder and all copies thereof in any medium.

4. Insider Information. Wolf agrees that as a result of the relationship
established hereunder with AtriCure, Wolf may periodically possess Confidential
Information that is considered to be “material” and “non-public” information.
The term “material” is defined to be information that a reasonable investor
would consider important in making an informed investment decision. The term
“non-public” means not made generally known by press release, conference call
open to the public, or in a filing with the Securities and Exchange Commission.
Wolf also understands that AtriCure has adopted an insider trading policy that
contains certain black-out periods for holders of material non-public
information. That black-out period starts on the first day of the last month of
a fiscal quarter and ends two full days following the release of earnings or
other material non-public financial information. Wolf agrees not to buy, sell,
pledge or otherwise trade, in AtriCure’s stock or options, or enter into any
transaction having the same economic effect, while in possession of material
non-public Confidential Information without pre-clearing such trades with
AtriCure’s Chief Financial Officer. Wolf understands that this Agreement further
requires that Wolf not disclose such Confidential Information to anyone until it
otherwise becomes publicly available.

 

--------------------------------------------------------------------------------

[*] Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

- 2 -

--------------------------------------------------------------------------------

5. Exclusivity. Wolf agrees that during the term of this Agreement, Wolf will
not consult in the field of cardiac surgery for any other company or entity that
manufactures, markets or sells or is researching or developing any device in the
field of invasive atrial fibrillation treatment, excluding (a) pharmacologic
treatments for atrial fibrillation, (b) pharmacology for stroke prevention,
(c) devices designed specifically for stroke prevention and (d) fat pad
isolation techniques developed for [*].

6. Term. This Agreement shall be effective as of the date hereof. This Agreement
shall terminate on December 31, 2009 unless otherwise terminated earlier by
either party hereto.

7. Termination for Cause.

(a) AtriCure shall have the right at any time to terminate this Agreement
immediately for cause, which shall include any of the following reasons:

i. If Wolf shall violate the provisions of Sections 2, 3, 4 or 5 of this
Agreement, or shall fail to comply with any other material term or condition of
this Agreement and Wolf does not cure such failure within thirty (30) days of
written notice thereof from AtriCure; or

ii. If Wolf shall (x) be convicted of a felony, or (y) commit an act of
dishonesty, fraud or embezzlement against AtriCure or any of its respective
subsidiaries or affiliates.

(b) Wolf has the right at any time to terminate this Agreement immediately for
cause if Wolf notifies AtriCure of any breach of AtriCure’s obligations
hereunder and AtriCure fails to cure such breach within thirty (30) days of
written notice thereof.

(c) At the date of termination, AtriCure shall have no further obligation to
Wolf and Wolf shall have no further rights or obligations hereunder, except as
set forth in Sections 2, 3 and 4 above, which provisions shall survive the
termination of this Agreement, and except for AtriCure’s obligation for unpaid
Royalties that have accrued but have not been paid as of the date of
termination.

8. Default. In the event of a breach or threatened breach of this Agreement by
either party hereto, each party acknowledges that the other party may not have
adequate remedy at law and may be entitled to seek such injunctive relief as may
be available to restrain the other party from violating the provisions hereof.
The prevailing party in any successful injunctive action shall be entitled to
reimbursement from the other party (including, without limitation, reasonable
attorneys’ fees) in connection with such action. Nothing herein shall prohibit
either party from pursuing other remedies available with respect to such breach
or threatened breach by the other party hereto, including the recovery of
damages.

9. Severability. If one or more of the provisions of this Agreement are deemed
invalid or unenforceable, such provision shall be ineffective and the remaining
provisions will continue in full force and effect.

 

--------------------------------------------------------------------------------

[*] Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

- 3 -

--------------------------------------------------------------------------------

10. Supersession. This Agreement constitutes the entire understanding between
AtriCure and Wolf with respect to the subject matter recited herein. The terms
and conditions set forth in this Agreement shall supersede any and all prior or
contemporaneous written or oral agreements regarding the subject matter
contained herein, including, without limitation, that certain agreement,
effective as of April 1, 2005, by and between AtriCure and Wolf.

11. Governing Law. This Agreement shall be governed by, construed and enforced
in accordance with the laws of the State of Ohio.

12. Amendment. This Agreement may be changed, modified or amended by a written
agreement of both parties hereto expressly referring to this Agreement and
stating that it changes, modifies or amends this Agreement or portions thereof.

13. Notices. All communications under this Agreement shall be in writing and
shall be delivered by hand or facsimile or mailed by overnight courier or by
registered or certified mail, postage prepaid to the parties at the addresses
first listed above. Any notice so addressed shall be deemed to be given: if
delivered by hand or facsimile, on the date of such delivery; if mailed by
courier, on the first business day following the date of such mailing; and if
mailed by registered or certified mail, on the third business day after the date
of such mailing, except in the case of common proof of late arrival of such
notice.

14. Waiver. Failure of any party at any time or times to require performance of
any provision hereof shall in no manner affect the right of such party at a
later time to enforce the same, and no waiver of any nature, whether by conduct
or otherwise, in any one or more instances, shall be deemed to be considered as
a further or continuing waiver of any other provision of this Agreement.

15. Counterparts. This Agreement may be executed in any of separate
counterparts, each of which shall be deemed to be an original, but which
together shall constitute one and the same instrument.

16. Assignment. This Agreement may not be assigned by AtriCure without the
consent of Wolf except to an affiliate of AtriCure, provided that such affiliate
assumes AtriCure’s obligations under this Agreement; provided, further, that if
AtriCure merges or effects a consolidation or share exchange with or into, or
sells or otherwise transfers substantially all of its assets to, another
business entity, AtriCure shall assign its rights and obligations hereunder to
that business entity without the consent of Wolf.

 

- 4 -

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, AtriCure and Wolf have caused this Agreement to be duly
executed and delivered as of this 21st day of November 2005.

 

ATRICURE, INC. By:  

/s/ David Drachman

Name:   Title:  

/s/ Randall K. Wolf, M.D.

Randall K. Wolf, M.D.

 

- 5 -

--------------------------------------------------------------------------------

Schedule A

 

    

Projected MIS

Revenue

   

% Revenue from

Dissector

Projected

   

Projected

Dissector

Revenue

    Royalty Rate    

Projected

Royalties Paid

Q4 2005

   $ [*]     [*] %   $ [*]     15.0 %   $ [*]

2006

   $ [*]     [*] %   $ [*]     10.5 %   $ [*]

2007

   $ [*]     [*] %   $ [*]     4.0 %   $ [*]

2008

   $ [*]     [*] %   $ [*]     2.5 %   $ [*]

2009

   $ [*]     [*] %   $ [*]     1.5 %   $ [*]                           

TOTAL

   $ [*]       $ [*]       $ [*]                           

Royalty % of MIS

     [*] %        

Royalty % of Dissector

         [*] %    

--------------------------------------------------------------------------------

[*] Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

- 6 -